Dupixent 300 mg/2mL

Dupilumab, the active ingredient in Dupixent 300 mg/2mL, is a monoclonal antibody presented as a 300 mg/2mL solution for subcutaneous use. It is indicated for the treatment of moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps in adults and children. GNH USA supplies Dupixent 300 mg/2mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Dupixent 300 mg/2mL is a biologic injection that targets specific proteins involved in the inflammatory process, helping to alleviate symptoms such as itching, redness, and swelling. It is designed to manage moderate-to-severe eczema and other inflammatory conditions.

Dupixent 300 mg/2mL is a biologic injection that blocks the IL-4 and IL-13 inflammation pathway, which is involved in various type 2 allergic conditions. It is used to treat the following conditions:

- Atopic dermatitis: Reduces symptoms such as itching, redness, and swelling in patients with moderate-to-severe eczema. - Asthma: Used as an add-on maintenance treatment for patients with uncontrolled asthma. - Chronic rhinosinusitis with nasal polyps: Helps to reduce the size of nasal polyps and improve symptoms. - Eosinophilic oesophagitis: Manages inflammation in the esophagus caused by eosinophils. - Prurigo nodularis: Alleviates itching and skin lesions associated with this condition.

Dupixent 300 mg/2mL may cause various side effects, ranging from common to serious or rare reactions.

Common Side Effects: - Injection site reactions, including erythema, edema, pruritus, pain, and swelling. - Conjunctivitis and allergic conjunctivitis, especially in patients with atopic dermatitis. - Oral herpes and eosinophilia, which is usually transient and asymptomatic. - Arthalgia and blistering or hematoma at the injection site. - Induration and dermatitis at the injection site. - Rash at the injection site.

Serious or Rare Side Effects: - Hypersensitivity reactions, including anaphylaxis and serum sickness, which are rare. - Keratitis, which can be serious and requires medical attention. - Eosinophilic conditions, such as vasculitis or eosinophilic pneumonia, sometimes after oral steroid taper.

Dupixent 300 mg/2mL should be used with caution and under the supervision of a healthcare professional. Important precautions include:

- Inform your healthcare provider about any allergies or medical conditions before starting treatment. - Avoid live vaccines during treatment with dupilumab. - Patients with helminth infections should be treated before initiating dupilumab. - Monitor for signs of hypersensitivity reactions, including anaphylaxis and serum sickness. - Regularly check for signs of keratitis and eosinophilic conditions. - Store at 2-8°C: Keep refrigerated, protect from light, and do not freeze or shake.

Dupixent 300 mg/2mL may interact with other medications, requiring careful monitoring or avoidance of certain combinations.

Major Interactions (Avoid): - Live vaccines: Avoid administration of live and live attenuated vaccines during treatment with dupilumab. - Immunosuppressive therapies: Caution is advised when combining with other immunosuppressive therapies.

Moderate Interactions (Monitor Closely): - Oral corticosteroids: Monitor for signs of eosinophilic conditions when tapering oral corticosteroids. - Other biologic therapies: Monitor for increased risk of infections or other adverse effects when used in combination with other biologic therapies. - Immunomodulators: Monitor for signs of increased immunosuppression or infections.